Sign In
Buy ADC
$72.03
-0.650 (-0.89%)
At Close: Jun 03, 2026
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
06:30pm, Thursday, 19'th Dec 2024
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Inf
Buy The Dip: 2 REITs Getting Way Too Cheap
09:00am, Thursday, 19'th Dec 2024
Some REITs suffered a dip in recent weeks. As a result, they have become cheap again. We highlight 2 of our favorite buy-the-dip opportunities.
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
07:17am, Thursday, 19'th Dec 2024
Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 qu
December's 5 Dividend Growth Stocks With 4.51%+ Yields
03:51pm, Wednesday, 18'th Dec 2024
Dividend growth stocks, though not often the most exciting, can offer the potential for growing wealth and passive income over the long run. Every month, we screen for potential opportunities, startin
2 REITs To Add To Your Christmas List And When To Buy For A Margin Of Safety
07:44am, Tuesday, 17'th Dec 2024
Agree Realty and VICI Properties are high-quality REITs with strong fundamentals and impressive total returns, but currently offer little margin of safety due to their run-up in share prices. Investin
Is Agree Realty a Millionaire Maker?
06:06pm, Saturday, 14'th Dec 2024
Net lease real estate investment trust (REIT) Agree Realty (ADC 1.39%) has a 4.1% dividend yield. That yield is a little higher than the 3.7% average for the REIT sector, but below the 5.6% you could
What I Wish I Knew Before Investing In REITs
09:00am, Saturday, 14'th Dec 2024
I have done well over time, but I could have done even better. I have made many mistakes over the years. I discuss 3 of my biggest regrets as a REIT investor.
3 REITs I'll Possibly Own Forever
07:00am, Saturday, 14'th Dec 2024
REITs have faced challenges like high inflation, rising interest rates, and the global pandemic, but conditions are improving, providing a tailwind for the sector. Realty Income, despite recent perfor
Agree Realty Declares Monthly Common and Preferred Dividends
04:05pm, Thursday, 12'th Dec 2024
ROYAL OAK, Mich., Dec. 12, 2024 /PRNewswire/ -- Agree Realty Corporation (NYSE: ADC) (the "Company") today announced that its Board of Directors has authorized, and the Company has declared, a mont
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
02:03pm, Thursday, 12'th Dec 2024
Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, u
2 REITs To Buy After The Rally
08:25am, Thursday, 12'th Dec 2024
REITs are up 40% on average over the past year. But some individual REITs are not up at all. I discuss 2 REITs that remain heavily discounted.
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
07:30am, Thursday, 12'th Dec 2024
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 lev
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
07:30am, Thursday, 12'th Dec 2024
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release
Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95
